Advanced search
Publication Cover
OncoImmunology Volume 8, 2019 - Issue 11
Submit an article Journal homepage
2,008
Views
36
CrossRef citations to date
0
Altmetric
Original Research

Enhancing direct cytotoxicity and response to immune checkpoint blockade following ionizing radiation with Wee1 kinase inhibition

Priya PatelTranslational Tumor Immunology Program, National Institute on Deafness and other Communication Disorders, National Institutes of Health, Bethesda, MD, USAView further author information
,
Lily SunTranslational Tumor Immunology Program, National Institute on Deafness and other Communication Disorders, National Institutes of Health, Bethesda, MD, USAView further author information
,
Yvette RobbinsTranslational Tumor Immunology Program, National Institute on Deafness and other Communication Disorders, National Institutes of Health, Bethesda, MD, USAView further author information
,
Paul E. ClavijoTranslational Tumor Immunology Program, National Institute on Deafness and other Communication Disorders, National Institutes of Health, Bethesda, MD, USAView further author information
,
Jay FriedmanTranslational Tumor Immunology Program, National Institute on Deafness and other Communication Disorders, National Institutes of Health, Bethesda, MD, USAView further author information
,
Christopher SilvinTumor Biology Section, National Institute on Deafness and other Communication Disorders, National Institutes of Health, Bethesda, MD, USAView further author information
,
Carter Van WaesTumor Biology Section, National Institute on Deafness and other Communication Disorders, National Institutes of Health, Bethesda, MD, USAView further author information
,
John CookRadiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAView further author information
,
James MitchellRadiation Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USAView further author information
&
Clint AllenTranslational Tumor Immunology Program, National Institute on Deafness and other Communication Disorders, National Institutes of Health, Bethesda, MD, USA;Department of Otolaryngology-Head and Neck Surgery, Johns Hopkins School of Medicine, Baltimore, MD, USACorrespondence[email protected]
View further author information
 show all
Article: e1638207 | Received 27 Feb 2019, Accepted 25 Jun 2019, Published online: 19 Jul 2019

Citations (36)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Sissel Hauge, Adrian Eek Mariampillai, Gro Elise Rødland, Lilli T. E. Bay, Helga B. Landsverk & Randi G. Syljuåsen. (2023) Expanding roles of cell cycle checkpoint inhibitors in radiation oncology. International Journal of Radiation Biology 99:6, pages 941-950.
Read now

Articles from other publishers (35)

Sandra Classen, Cordula Petersen & Kerstin Borgmann. (2023) Crosstalk between immune checkpoint and DNA damage response inhibitors for radiosensitization of tumors. Strahlentherapie und Onkologie 199:12, pages 1152-1163.
Crossref
Vanessa Klapp, Beatriz Álvarez-Abril, Giuseppe Leuzzi, Guido Kroemer, Alberto Ciccia & Lorenzo Galluzzi. (2023) The DNA Damage Response and Inflammation in Cancer. Cancer Discovery 13:7, pages 1521-1545.
Crossref
Yingyao Quan, Wei Li, Rongrong Yan, Jing Cheng, Heng Xu & Lin Chen. (2023) Tumor cuproptosis and immune infiltration improve survival of patients with hepatocellular carcinoma with a high expression of ferredoxin 1. Frontiers in Oncology 13.
Crossref
Deqian Xie, Bowen Jiang, Shijin Wang, Qifei Wang & Guangzhen Wu. (2023) The mechanism and clinical application of DNA damage repair inhibitors combined with immune checkpoint inhibitors in the treatment of urologic cancer. Frontiers in Cell and Developmental Biology 11.
Crossref
Tiffany Toni, Ramya Viswanathan, Yvette Robbins, Sreenivasulu Gunti, Xinping Yang, Angel Huynh, Hui Cheng, Anastasia Sowers, James Mitchell, Clint Allen, Ethan Morgan & Carter Van Waes. (2023) Combined Inhibition of IAPs and WEE1 Enhances TNFα- and Radiation-Induced Cell Death in Head and Neck Squamous Carcinoma. Cancers 15:4, pages 1029.
Crossref
Chenxi Wu, Yingjie Shao & Wendong Gu. (2023) Immunotherapy combined with radiotherapy to reverse immunosuppression in microsatellite stable colorectal cancer. Clinical and Translational Oncology 25:7, pages 1916-1928.
Crossref
Alexandre André B. A. da Costa, Dipanjan Chowdhury, Geoffrey I. Shapiro, Alan D. D’Andrea & Panagiotis A. Konstantinopoulos. (2022) Targeting replication stress in cancer therapy. Nature Reviews Drug Discovery 22:1, pages 38-58.
Crossref
Katharina Hintelmann, Cordula Petersen & Kerstin Borgmann. (2022) Radiotherapeutic Strategies to Overcome Resistance of Breast Cancer Brain Metastases by Considering Immunogenic Aspects of Cancer Stem Cells. Cancers 15:1, pages 211.
Crossref
Congqi Shi, Kaiyu Qin, Anqi Lin, Aimin Jiang, Quan Cheng, Zaoqu Liu, Jian Zhang & Peng Luo. (2022) The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy. Journal of Experimental & Clinical Cancer Research 41:1.
Crossref
Cristina P Rodriguez, Hyunseok Kang, Jessica L Geiger, Barbara Burtness, Christine H Chung, Curtis R Pickering, Carole Fakhry, Quynh Thu Le, Sue S Yom, Thomas J Galloway, Erica Golemis, Alice Li, Jeffrey Shoop, Stuart Wong, Ranee Mehra, Heath Skinner, Nabil F Saba, Elsa R Flores, Jeffrey N Myers, James M Ford, Rachel Karchin, Robert L Ferris, Charles Kunos, Jean M Lynn & Shakun Malik. (2022) Clinical Trial Development in TP53- Mutated Locally Advanced and Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma . JNCI: Journal of the National Cancer Institute.
Crossref
Michihisa Kono, Shin Saito, Ann Marie Egloff, Clint T. Allen & Ravindra Uppaluri. (2022) The mouse oral carcinoma (MOC) model: A 10-year retrospective on model development and head and neck cancer investigations. Oral Oncology 132, pages 106012.
Crossref
Charleen M. L. Chan Wah Hak, Antonio Rullan, Emmanuel C. Patin, Malin Pedersen, Alan A. Melcher & Kevin J. Harrington. (2022) Enhancing anti-tumour innate immunity by targeting the DNA damage response and pattern recognition receptors in combination with radiotherapy. Frontiers in Oncology 12.
Crossref
Yuewen Zhang, Lei Wu, Zhao Wang, Jinpeng Wang, Shrabasti Roychoudhury, Bartlomiej Tomasik, Gang Wu, Geng Wang, Xinrui Rao & Rui Zhou. (2022) Replication Stress: A Review of Novel Targets to Enhance Radiosensitivity-From Bench to Clinic. Frontiers in Oncology 12.
Crossref
Luisa Maresca, Barbara Stecca & Laura Carrassa. (2022) Novel Therapeutic Approaches with DNA Damage Response Inhibitors for Melanoma Treatment. Cells 11:9, pages 1466.
Crossref
Zejia Yang, Jipei Liao, Rena G. Lapidus, Xiaoxuan Fan, Ranee Mehra, Kevin J. Cullen & Hancai Dan. (2022) Targeting Wee1 kinase to suppress proliferation and survival of cisplatin-resistant head and neck squamous cell carcinoma. Cancer Chemotherapy and Pharmacology 89:4, pages 469-478.
Crossref
Emmanuel C Patin, Magnus T Dillon, Pablo Nenclares, Lorna Grove, Heba Soliman, Isla Leslie, Davina Northcote, Galabina Bozhanova, Eva Crespo-Rodriguez, Holly Baldock, Harriet Whittock, Gabriella Baker, Joan Kyula, Jeane Guevara, Alan A Melcher, James Harper, Hormas Ghadially, Simon Smith, Malin Pedersen, Martin McLaughlin & Kevin J Harrington. (2022) Harnessing radiotherapy-induced NK-cell activity by combining DNA damage–response inhibition and immune checkpoint blockade. Journal for ImmunoTherapy of Cancer 10:3, pages e004306.
Crossref
Amirali B. Bukhari, Gordon K. Chan & Armin M. Gamper. (2022) Targeting the DNA Damage Response for Cancer Therapy by Inhibiting the Kinase Wee1. Frontiers in Oncology 12.
Crossref
Giulia Petroni, Lewis C. Cantley, Laura Santambrogio, Silvia C. Formenti & Lorenzo Galluzzi. (2021) Radiotherapy as a tool to elicit clinically actionable signalling pathways in cancer. Nature Reviews Clinical Oncology 19:2, pages 114-131.
Crossref
Tijana Vlatkovic, Marlon R. Veldwijk, Frank A. Giordano & Carsten Herskind. (2022) Targeting Cell Cycle Checkpoint Kinases to Overcome Intrinsic Radioresistance in Brain Tumor Cells. Cancers 14:3, pages 701.
Crossref
Sabine Mueller, Tabitha Cooney, Xiaodong Yang, Sharmistha Pal, Ralph Ermoian, Amar Gajjar, Xiaowei Liu, Komal Prem, Charles G Minard, Joel M Reid, Marvin Nelson, Daphne Haas-Kogan, Elizabeth Fox & Brenda J Weigel. (2022) Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Children’s Oncology Group phase I consortium study. Neuro-Oncology Advances 4:1.
Crossref
Maria Rita Fabbrizi & Jason L. Parsons. (2022) Cell death mechanisms in head and neck cancer cells in response to low and high-LET radiation. Expert Reviews in Molecular Medicine 24.
Crossref
Lingling Zhu, Jiewei Liu, Jiang Chen & Qinghua Zhou. (2021) The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers. Journal of Hematology & Oncology 14:1.
Crossref
Xiangbing Meng, Jason Z. Gao, Sean Michael T. Gomendoza, John W. Li & Shujie Yang. (2021) Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations. Frontiers in Medicine 8.
Crossref
Minlin Jiang, Keyi Jia, Lei Wang, Wei Li, Bin Chen, Yu Liu, Hao Wang, Sha Zhao, Yayi He & Caicun Zhou. (2021) Alterations of DNA damage response pathway: Biomarker and therapeutic strategy for cancer immunotherapy. Acta Pharmaceutica Sinica B 11:10, pages 2983-2994.
Crossref
Gro Elise Rødland, Sissel Hauge, Grete Hasvold, Lilli T. E. Bay, Tine T. H. Raabe, Mrinal Joel & Randi G. Syljuåsen. (2021) Differential Effects of Combined ATR/WEE1 Inhibition in Cancer Cells. Cancers 13:15, pages 3790.
Crossref
N.E. Donlon, R. Power, C. Hayes, J.V. Reynolds & J. Lysaght. (2021) Radiotherapy, immunotherapy, and the tumour microenvironment: Turning an immunosuppressive milieu into a therapeutic opportunity. Cancer Letters 502, pages 84-96.
Crossref
Jinhua Zhang, Jing Si, Lu Gan, Rong Zhou, Menghuan Guo & Hong Zhang. (2020) Harnessing the targeting potential of differential radiobiological effects of photon versus particle radiation for cancer treatment. Journal of Cellular Physiology 236:3, pages 1695-1711.
Crossref
Win Topatana, Sarun Juengpanich, Shijie Li, Jiasheng Cao, Jiahao Hu, Jiyoung Lee, Kenneth Suliyanto, Diana Ma, Bin Zhang, Mingyu Chen & Xiujun Cai. (2020) Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation. Journal of Hematology & Oncology 13:1.
Crossref
Kate M. MacDonald, Soraya Benguerfi & Shane M. Harding. (2020) Alerting the immune system to DNA damage: micronuclei as mediators. Essays in Biochemistry 64:5, pages 753-764.
Crossref
Carmelina Antonella Iannuzzi, Paola Indovina, Iris Maria Forte, Sarah Di Somma, Anna Maria Malfitano, Martina Bruno, Giuseppe Portella, Francesca Pentimalli & Antonio Giordano. (2020) Pharmacological Inhibition of WEE1 Potentiates the Antitumoral Effect of the dl922-947 Oncolytic Virus in Malignant Mesothelioma Cell Lines. International Journal of Molecular Sciences 21:19, pages 7333.
Crossref
Hui Yi Chew, Riccardo Dolcetti & Fiona Simpson. (2020) Scientifically based combination therapies with immuno‐oncology checkpoint inhibitors. British Journal of Clinical Pharmacology 86:9, pages 1711-1725.
Crossref
Bin Wang, Lin Sun, Zhiyong Yuan & Zhen Tao. (2020) Wee1 kinase inhibitor AZD1775 potentiates CD8+ T cell-dependent antitumour activity via dendritic cell activation following a single high dose of irradiation. Medical Oncology 37:8.
Crossref
Martin McLaughlin, Emmanuel C. Patin, Malin Pedersen, Anna Wilkins, Magnus T. Dillon, Alan A. Melcher & Kevin J. Harrington. (2020) Inflammatory microenvironment remodelling by tumour cells after radiotherapy. Nature Reviews Cancer 20:4, pages 203-217.
Crossref
Nicole C. Schmitt & Robert L. Ferris. 2020. Novel Therapies in Head and Neck Cancer: Beyond the Horizon. Novel Therapies in Head and Neck Cancer: Beyond the Horizon 117 142 .
Matthew T. McMillan, Theodore S. Lawrence & Meredith A. Morgan. 2020. Molecular Targeted Radiosensitizers. Molecular Targeted Radiosensitizers 191 218 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.